 CAMBRIDGE, Mass., June 15, 2021 GLOBE NEWSWIRE -- Spero Therapeutics, Inc. Nasdaq: SPRO, a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the initiation of two Phase 1 trials of SPR206, an intravenously IV-administered next-generation polymyxin product candidate. SPR206 was derived from Speros potentiator platform and is being developed to treat serious multi-drug resistant MDR Gram-negative infections in the hospital setting. These trials, which are now open for enrollment, include a bronchoalveolar lavage BAL clinical trial assessing the penetration of SPR206 into the pulmonary compartment and a renal impairment clinical trial. 